News >

CTC AR-V7 Assay Shows Promise as Treatment Guide in mCRPC

Jason Harris
Published: Tuesday, Jul 17, 2018

Howard I. Scher, MD

Howard I. Scher, MD
An assay for nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) identified patients with metastatic castration-resistant prostate cancer (mCRPC) who had better outcomes from treatment with taxanes, and those who did better with androgen receptor-signaling (ARS) inhibitors. AR-V7–positive patients had superior outcomes with taxanes while AR-V7–negative patents had better outcomes with ARS inhibitor treatment.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication